• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Tandem Diabetes Care Inc.

    11/13/25 9:01:10 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care
    Get the next $TNDM alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    TANDEM DIABETES CARE INC

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    875372203

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    875372203


    1Names of Reporting Persons

    ArrowMark Colorado Holdings, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,691,198.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,691,198.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,691,198.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.46 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    TANDEM DIABETES CARE INC
    (b)Address of issuer's principal executive offices:

    12400 HIGH BLUFF DRIVE, San Diego, CA, 92130
    Item 2. 
    (a)Name of person filing:

    ArrowMark Colorado Holdings, LLC
    (b)Address or principal business office or, if none, residence:

    100 Fillmore Street, Suite 325, Denver, Colorado 80206
    (c)Citizenship:

    Delaware, United States
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    875372203
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    3,691,198
    (b)Percent of class:

    5.46%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    3,691,198

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    3,691,198

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    ArrowMark Colorado Holdings, LLC
     
    Signature:Richard Grove
    Name/Title:Richard Grove | Chief Compliance Officer
    Date:11/13/2025
    Get the next $TNDM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TNDM

    DatePrice TargetRatingAnalyst
    10/21/2025$15.00Hold
    Stifel
    9/8/2025$22.00Outperform
    Oppenheimer
    8/12/2025$10.35Sell → Neutral
    Citigroup
    8/7/2025$14.00Overweight → Neutral
    Piper Sandler
    7/9/2025$14.00Neutral → Sell
    Citigroup
    6/16/2025$24.00Hold
    Truist
    4/10/2025$20.00Neutral
    Mizuho
    3/5/2025$45.00 → $22.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $TNDM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 28, 2025 - FDA Roundup: February 28, 2025

    For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

    2/28/25 5:00:47 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    November 7, 2023 - FDA Roundup: November 7, 2023

    For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse

    11/7/23 3:38:18 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tandem Diabetes Care Announces Appointment of Sandra Beaver to Board of Directors

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Sandra Beaver to its board of directors effective November 7, 2025. Ms. Beaver joins the board as an independent director and will serve on the board's Audit Committee and Cybersecurity and Data Oversight Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112460451/en/Sandra Beaver joins Tandem Diabetes Care Board of Directors. "We welcome Sandra to our Board of Directors at this pivotal stage in Tandem's evolution," said John Sheridan, president and CEO. "Sandra is a dynamic finance

    11/12/25 9:00:00 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Mobi Receives FDA Clearance for Use with Android Smartphones

    By adding compatibility with the Android platform, Tandem Mobi is expanding its connected-care ecosystem Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Android version of the Tandem Mobi mobile app. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110799415/en/Tandem Mobi Receives FDA Clearance for Use with Android Smartphones Tandem Mobi, the world's smallest, durable automated insulin delivery system 1, is powered by Control-IQ+ technology. Proven Control-IQ+ benefits include: Day 1 improvem

    11/10/25 8:30:00 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care Announces Third Quarter 2025 Financial Results

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2025 and reaffirmed full year 2025 guidance. Third Quarter 2025 and Recent Highlights Achieved record third quarter sales both in the United States (U.S.) and internationally Demonstrated year-over-year and sequential gross margin improvement Progressed multi-channel initiative by: Increasing pharmacy benefit coverage for Tandem Mobi to more than 40% of U.S. lives Introducing t:slim X2 supplies through a pharmacy benefit Received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for extend

    11/6/25 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Tandem Diabetes Care with a new price target

    Stifel resumed coverage of Tandem Diabetes Care with a rating of Hold and set a new price target of $15.00

    10/21/25 7:22:24 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Oppenheimer initiated coverage on Tandem Diabetes Care with a new price target

    Oppenheimer initiated coverage of Tandem Diabetes Care with a rating of Outperform and set a new price target of $22.00

    9/8/25 8:59:21 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care upgraded by Citigroup with a new price target

    Citigroup upgraded Tandem Diabetes Care from Sell to Neutral and set a new price target of $10.35

    8/12/25 7:47:28 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Leadership Updates

    Live Leadership Updates

    View All

    Tandem Diabetes Care Announces Appointment of Sandra Beaver to Board of Directors

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Sandra Beaver to its board of directors effective November 7, 2025. Ms. Beaver joins the board as an independent director and will serve on the board's Audit Committee and Cybersecurity and Data Oversight Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112460451/en/Sandra Beaver joins Tandem Diabetes Care Board of Directors. "We welcome Sandra to our Board of Directors at this pivotal stage in Tandem's evolution," said John Sheridan, president and CEO. "Sandra is a dynamic finance

    11/12/25 9:00:00 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620151195/en/Jean-Claude "JC" Kyrillos (Photo: Business Wire) "JC brings deep experience in healthcare and a great balance of technical, operational, and leadership skills from multipl

    6/20/24 9:00:00 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care, Inc investors: Please contact the Portnoy Law Firm to recover your losses; November 2, 2023 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio

    11/7/23 3:47:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Sheridan John F bought $102,318 worth of shares (10,000 units at $10.23), increasing direct ownership by 10% to 106,327 units (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    8/11/25 6:15:44 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh bought $149,404 worth of shares (13,720 units at $10.89) (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    8/11/25 5:18:51 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & Chief Operating Officer Kyrillos Jean-Claude bought $190,966 worth of shares (10,538 units at $18.12) (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    3/11/25 6:06:01 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Financials

    Live finance-specific insights

    View All

    Tandem Diabetes Care Announces Third Quarter 2025 Financial Results

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2025 and reaffirmed full year 2025 guidance. Third Quarter 2025 and Recent Highlights Achieved record third quarter sales both in the United States (U.S.) and internationally Demonstrated year-over-year and sequential gross margin improvement Progressed multi-channel initiative by: Increasing pharmacy benefit coverage for Tandem Mobi to more than 40% of U.S. lives Introducing t:slim X2 supplies through a pharmacy benefit Received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for extend

    11/6/25 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care to Announce Third Quarter 2025 Financial Results on November 6, 2025

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2025 results after the financial markets close on Thursday, November 6, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BIc60

    10/2/25 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual Guidance

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2025 and provided full year 2025 guidance. Second Quarter 2025 Highlights Achieved record second quarter sales both in the United States (U.S.) and internationally. Demonstrated year-over-year and sequential gross margin improvement. Initiated an early access program for the t:slim X2™ insulin pump with Control-IQ+ technology integrated with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring sensor in the U.S. Progressed multichannel initiative to include t:slim X2 supplies as a pharmacy benefit beg

    8/6/25 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Beaver Sandra

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    11/25/25 4:10:33 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    New insider Beaver Sandra claimed no ownership of stock in the company (SEC Form 3)

    3 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    11/25/25 4:09:11 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & Chief Admin. Officer Morrison Susan covered exercise/tax liability with 744 shares and converted options into 2,599 shares, increasing direct ownership by 5% to 40,917 units (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    11/19/25 4:07:14 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Tandem Diabetes Care Inc.

    SCHEDULE 13G - TANDEM DIABETES CARE INC (0001438133) (Subject)

    11/13/25 9:01:10 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

    11/12/25 9:02:09 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Tandem Diabetes Care Inc.

    10-Q - TANDEM DIABETES CARE INC (0001438133) (Filer)

    11/6/25 4:15:27 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

    SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

    11/14/24 4:15:44 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

    SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

    9/9/24 10:40:31 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tandem Diabetes Care Inc.

    SC 13G - TANDEM DIABETES CARE INC (0001438133) (Subject)

    2/14/24 7:37:31 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care